



10581 Roselle Street, Suite 115
San Diego, CA 92121
415.967.1220 **direct** 415.235.1294 **mobile**
ablexis.com

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center

Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse Platform

SAN DIEGO, Calif. – **October 9, 2018** – [Ablexis, LLC](http://ablexis.com), a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Memorial Sloan Kettering Cancer Center. The license grants Memorial Sloan Kettering rights to research, develop and commercialize, with rights to sub-license, certain AlivaMab antibodies against a specific target.

The antibodies were generated by the Tri-Institutional Therapeutics Discovery Institute, Inc. (<https://www.tritdi.org/>) under a non-exclusive license of AlivaMab Mouse announced in January 2017. Under this new license, Ablexis could receive clinical development and approval milestones and a running revenue share of sales of products derived from the AlivaMab antibodies.

“The AlivaMab Mouse is an increasingly validated platform for generating antibodies with qualities desirable in a potential therapeutic,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This agreement with Memorial Sloan Kettering exemplifies the speed and value-add that the AlivaMab Mouse can bring to a therapeutic antibody discovery program.”

The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR-Ts and for a range of applications including:

- Sequence diverse panels of mAbs
- Epitope diverse panels of mAbs
- Challenging targets such as GPCRs
- Challenging design goals such as IC₅₀ values of very low picomolar

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com.

###

Media Contact:

Christine Quern
cq@christinequern.com



10581 Roselle Street, Suite 115
San Diego, CA 92121
415.967.1220 **direct** 415.235.1294 **mobile**
ablexis.com

617-650-8497